022 82 44 44

A Revolutionary Blood Test for Patients with Suspected Cancer

The accepted standard for ruling out or confirming cancer when it is suspected is invasive tissue sampling, such as a biopsy or surgery. However, subsequent histopathological examination often reveals benign conditions in a significant number of patients, which do not present significant health risks. This means that many patients without cancer have to undergo invasive procedures that are associated with various risks (pain, bleeding, infections, etc.). Additionally, there are situations where tissue sampling is not possible, increasing the likelihood of “missing” the cancer.
Thus, there are two unmet clinical needs when cancer is suspected in patients:

The need to identify patients with a high probability of having cancer, who would require an invasive biopsy to confirm the diagnosis (a process known as diagnostic 'triage'). This approach could reduce the necessity and associated risks of invasive procedures in patients with a low probability of cancer.
The need for a safe and reliable minimally invasive test that can provide diagnostically relevant information to support clinical decision-making in cases when obtaining tissue samples invasively is challenging.

Trublood is a non-invasive diagnostic test designed to detect breast, prostate, colorectal, lung cancers as well as pancreaticobiliary and central nervous system cancer in patients with a clinical suspicion of malignancy
Based on a safe blood test

Trublood tests the patient's blood sample for the presence of "circulating tumor cells" (CTCs), which are released into the bloodstream by solid tumors at any stage of malignancy. CTCs are an ideal and accurate biomarker for cancer detection, as they are intact malignant cells bearing the imprint of the parent tumor. CTCs are not found in healthy individuals or in patients with benign tumors.
The detection of CTCs in a patient's blood sample indicates a high probability of latent cancer in a specific organ or tissue, and, as a result, the patient may be recommended for additional diagnostic procedures (such as invasive biopsy). Conversely, the absence of CTCs in the blood sample suggests a low probability of hidden cancer.

For professional use only
Developed, validated, and certified by Datar Cancer Genetics

Advantages of Liquid Biopsy

Liquid Biopsy
Invasive Biopsy

Minimally Invasive
Absolutely Invasive Method
No need for hospitalization/anesthesia
Can be performed only in a hospital/under anesthesia
No pain, no stitches, no scars
Painful, may require stitches
No risk
Risk of "seeding" tumor cells
No risk of organ damage or bleeding
May carry risks for organs such as the lungs, liver, and pancreas
Provides real-time data and covers all active areas
May affect tumor heterogeneity
Can be performed as often as needed
Serial/sequential biopsies are complex or impractical
Reliable even if the primary tumor or metastases are not detected
If the primary tumor is poorly visualized, a biopsy may be impractical

Liquid Biopsy

Minimally Invasive
No need for hospitalization/anesthesia
No pain, no stitches, no scars
No risk
No risk of organ damage or bleeding
Provides real-time data and covers all active areas
Can be performed as often as needed
Reliable even if the primary tumor or metastases are not detected

Invasive Biopsy

Absolutely Invasive Method
Can be performed only in a hospital/under anesthesia
Painful, may require stitches
Risk of "seeding" tumor cells
May carry risks for organs such as the lungs, liver, and pancreas
May affect tumor heterogeneity
Serial/sequential biopsies are complex or impractical
If the primary tumor is poorly visualized, a biopsy may be impractical

The unique features of Trublood have been confirmed in clinical studies
(40 000+ healthy people and patients)

Advanced technology

Malignant tumors at all stages release cells and non-cellular components (exosomes, proteins, and nucleic acids) into the bloodstream, which can be analyzed using appropriate technologies. This principle underlies the minimally invasive technology of “liquid biopsy”, based on the assessment of biological samples obtained non-invasively, such as through a blood draw.
Circulating tumor cells (CTCs) are intact, nucleated malignant cells that have entered the bloodstream from a cancerous tumor. While some CTCs are destroyed by various mechanisms (such as immune clearance or apoptosis), others survive, spread (metastasize) to different organs, and lead to the formation of secondary tumors. CTCs may exist individually or in clusters, known as circulating tumor-associated cells. These clusters have greater survivability because they are better protected from immune surveillance and are able to avoid anoikis (cell death due to loss of cell-to-cell contact).

CTCs are highly specific for the presence of cancer (compared to DNA/RNA) and are not found in the blood samples of healthy individuals or those with benign tumors.
Using primary negative enrichment with an epigenetically active stabilizing medium, Trublood ensures the survival of malignant cells (resistant to apoptosis) while allowing non-malignant cells to undergo apoptosis (programmed cell death). Detection of CTCs is based on direct visualization rather than indirect assessments, representing a "liquid biopsy" of the tumor. Subsequent analysis using multiplex fluorescent immunocytochemistry of tissue-specific markers on these cells helps determine cancer types and their likely organ of origin.

Features

High Sensitivity
Reliable detection of CTCs in localized (including in situ), locally advanced, and metastatic cancers, regardless of age, stage, or molecular subtypes
High Specificity
Extremely low risk of false-positive results
Accurate Tissue and Organ Information
Provides critical guidance for further diagnostic procedures
Strict Quality Control
Every positive result is approved by a licensed pathologist

Who is the test recommended for?

Patients with clinical suspicion of cancer, for whom invasive biopsy is recommended (palpable tumor, clinical laboratory and radiological data, colonoscopy, etc.)
Patients for whom standard diagnostic procedures (e.g., radiological data, invasive biopsy) are inconclusive or do not correspond to clinical observations
Suspected metastatic recurrence to rule out a new primary tumor.

Patients with clinical suspicion of cancer, for whom invasive biopsy is recommended (palpable tumor, clinical laboratory and radiological data, colonoscopy, etc.)
Patients for whom standard diagnostic procedures (e.g., radiological data, invasive biopsy) are inconclusive or do not correspond to clinical observations
Suspected metastatic recurrence to rule out a new primary tumor.

Decisions

Trublood Prostate

Prostate

Trublood Pancreaticobiliary

Pаncreas, Gallbladder, Bile Ducts

Trublood Lung

Lungs

Trublood Breast

Breast

Trublood CNS

Central Nervous System

Trublood Colorectum

Colorectal

Decided to take the test!

Book your first consultation with a doctor

The doctor will inform you about the upcoming testing, answer any questions you may have, and then ask you to sign an informed consent form for the test. Then, the doctor will complete a special form (application) according to the requirements of Trublood